Dexchlorpheniramine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dexchlorpheniramine
Accession Number
DB13679
Type
Small Molecule
Groups
Experimental, Investigational
Description

Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjuctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signalling by competing with histamine for cell receptor sites on effector cells.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
3Q9Q0B929N
CAS number
25523-97-1
Weight
Average: 274.79
Monoisotopic: 274.1236763
Chemical Formula
C16H19ClN2
InChI Key
SOYKEARSMXGVTM-HNNXBMFYSA-N
InChI
InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
IUPAC Name
[(3S)-3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
SMILES
CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Dexchlorpheniramine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Illicit
AmphetamineAmphetamine may decrease the sedative activities of Dexchlorpheniramine.Approved, Illicit, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Dexchlorpheniramine.Approved, Illicit
Benzylpenicilloyl PolylysineDexchlorpheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Dexchlorpheniramine.Approved, Investigational
ChlorphentermineChlorphentermine may decrease the sedative activities of Dexchlorpheniramine.Illicit, Withdrawn
DextroamphetamineDextroamphetamine may decrease the sedative activities of Dexchlorpheniramine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative activities of Dexchlorpheniramine.Approved, Illicit
GepefrineGepefrine may decrease the sedative activities of Dexchlorpheniramine.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexchlorpheniramine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Dexchlorpheniramine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Dexchlorpheniramine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Dexchlorpheniramine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Dexchlorpheniramine.Investigational
MephentermineMephentermine may decrease the sedative activities of Dexchlorpheniramine.Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Dexchlorpheniramine.Approved, Illicit
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Dexchlorpheniramine.Experimental
MidomafetamineMidomafetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Illicit, Investigational
MMDAMMDA may decrease the sedative activities of Dexchlorpheniramine.Experimental, Illicit
PhenterminePhentermine may decrease the sedative activities of Dexchlorpheniramine.Approved, Illicit
PseudoephedrinePseudoephedrine may decrease the sedative activities of Dexchlorpheniramine.Approved
RitobegronRitobegron may decrease the sedative activities of Dexchlorpheniramine.Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0240218
KEGG Compound
C06946
PubChem Compound
33036
PubChem Substance
347829309
ChemSpider
30576
ChEBI
4464
ChEMBL
CHEMBL1201353
Wikipedia
Dexchlorpheniramine
ATC Codes
R06AB02 — DexchlorpheniramineR06AB52 — Dexchlorpheniramine, combinations

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentProgressive Multiple Sclerosis1
3RecruitingPreventionHemodynamics Instability / Vasoplegic Syndrome1
3RecruitingTreatmentDisseminated Sclerosis1
3Unknown StatusTreatmentInsect Bites2
3Unknown StatusTreatmentSunburn2
3Unknown StatusTreatmentViral Infections of the Upper Respiratory Tract1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0519 mg/mLALOGPS
logP3.74ALOGPS
logP3.58ChemAxon
logS-3.7ALOGPS
pKa (Strongest Basic)9.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity80.85 m3·mol-1ChemAxon
Polarizability30.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0190000000-f6ef5e736260c9c22a16
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uy0-0960000000-24a36e80af50293ed70d

Taxonomy

Description
This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pheniramines
Direct Parent
Pheniramines
Alternative Parents
Chlorobenzenes / Aralkylamines / Aryl chlorides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Pheniramine / Chlorobenzene / Halobenzene / Aralkylamine / Aryl chloride / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
chlorphenamine (CHEBI:4464)

Drug created on June 23, 2017 14:46 / Updated on May 02, 2018 00:37